Your browser doesn't support javascript.
loading
Reconsidering Routine Repeat Group and Screens During Pregnancy-Personalizing Pregnancy Care.
Tran, Ann; Clarke, Gwen; Callum, Jeannie L; Smith, Graeme; Somerset, David; Thorne, Julie; Lieberman, Lani.
Afiliação
  • Tran A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC. Electronic address: ann.tran2@fraserhealth.ca.
  • Clarke G; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB.
  • Callum JL; Department of Pathology and Molecular Medicine, Kingston Health Sciences Centre, Queen's University, Kingston, ON; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
  • Smith G; Department of Obstetrics and Gynaecology, Kingston Health Sciences Centre, Queen's University, Kingston, ON.
  • Somerset D; Department of Obstetrics and Gynecology, University of Calgary, Calgary, AB.
  • Thorne J; Department of Obstetrics and Gynaecology, Women's College Hospital, Sinai Health Systems and University of Toronto, Toronto, ON.
  • Lieberman L; Laboratory Medicine Program, University Health Network, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON.
J Obstet Gynaecol Can ; 46(5): 102351, 2024 May.
Article em En | MEDLINE | ID: mdl-38199432
ABSTRACT
The group and screen (G&S) are performed in early pregnancy to identify clinically significant antibodies (CSA) that may necessitate fetal monitoring for hemolysis/anemia or affect RhIg eligibility. Guidelines vary, including differences between RhD-positive and negative patients, but typically, the G&S is repeated at 28 weeks, and sometimes pre-delivery. We reviewed data showing a low risk (0.01%-0.43%) of detecting a new CSA in late gestation (late alloimmunization) and the risk of late alloimmunization causing severe hemolysis/anemia is even lower at <0.01%. Routinely repeating a G&S at 28 weeks and delivery may not be necessary for healthy, low-risk pregnancies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isoimunização Rh Tipo de estudo: Guideline Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Isoimunização Rh Tipo de estudo: Guideline Limite: Female / Humans / Pregnancy Idioma: En Ano de publicação: 2024 Tipo de documento: Article